113 related articles for article (PubMed ID: 9365379)
1. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis.
Redford EJ; Smith KJ; Gregson NA; Davies M; Hughes P; Gearing AJ; Miller K; Hughes RA
Brain; 1997 Oct; 120 ( Pt 10)():1895-905. PubMed ID: 9365379
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.
Clements JM; Cossins JA; Wells GM; Corkill DJ; Helfrich K; Wood LM; Pigott R; Stabler G; Ward GA; Gearing AJ; Miller KM
J Neuroimmunol; 1997 Apr; 74(1-2):85-94. PubMed ID: 9119983
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase expression during experimental autoimmune neuritis.
Hughes PM; Wells GM; Clements JM; Gearing AJ; Redford EJ; Davies M; Smith KJ; Hughes RA; Brown MC; Miller KM
Brain; 1998 Mar; 121 ( Pt 3)():481-94. PubMed ID: 9549524
[TBL] [Abstract][Full Text] [Related]
4. Effect of a matrix metalloproteinase inhibitor (BB-1101) on nerve regeneration.
Demestre M; Gregson NA; Smith KJ; Miller KM; Gearing AJ; Hughes RA
Ann N Y Acad Sci; 1999 Jun; 878():658-61. PubMed ID: 10415800
[No Abstract] [Full Text] [Related]
5. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome.
Kieseier BC; Clements JM; Pischel HB; Wells GM; Miller K; Gearing AJ; Hartung HP
Ann Neurol; 1998 Apr; 43(4):427-34. PubMed ID: 9546322
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.
Leib SL; Clements JM; Lindberg RL; Heimgartner C; Loeffler JM; Pfister LA; Täuber MG; Leppert D
Brain; 2001 Sep; 124(Pt 9):1734-42. PubMed ID: 11522576
[TBL] [Abstract][Full Text] [Related]
7. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing.
DiMartino M; Wolff C; High W; Stroup G; Hoffman S; Laydon J; Lee JC; Bertolini D; Galloway WA; Crimmin MJ; Davis M; Davies S
Inflamm Res; 1997 Jun; 46(6):211-5. PubMed ID: 9243304
[TBL] [Abstract][Full Text] [Related]
8. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases.
Matyszak MK; Perry VH
J Neuroimmunol; 1996 Sep; 69(1-2):141-9. PubMed ID: 8823386
[TBL] [Abstract][Full Text] [Related]
9. Distribution of inducible nitric oxide synthase and tumor necrosis factor-alpha in the peripheral nervous system of Lewis rats during ascending paresis and spontaneous recovery from experimental autoimmune neuritis.
De La Hoz CL; Castro FR; Santos LM; Langone F
Neuroimmunomodulation; 2010; 17(1):56-66. PubMed ID: 19816058
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors.
Liedtke W; Cannella B; Mazzaccaro RJ; Clements JM; Miller KM; Wucherpfennig KW; Gearing AJ; Raine CS
Ann Neurol; 1998 Jul; 44(1):35-46. PubMed ID: 9667591
[TBL] [Abstract][Full Text] [Related]
11. Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis.
Weishaupt A; Gold R; Hartung T; Gaupp S; Wendel A; Brück W; Toyka KV
J Neuropathol Exp Neurol; 2000 May; 59(5):368-76. PubMed ID: 10888366
[TBL] [Abstract][Full Text] [Related]
12. Chrysin attenuates experimental autoimmune neuritis by suppressing immuno-inflammatory responses.
Xiao J; Zhai H; Yao Y; Wang C; Jiang W; Zhang C; Simard AR; Zhang R; Hao J
Neuroscience; 2014 Mar; 262():156-64. PubMed ID: 24412705
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis.
Steinmann-Niggli K; Ziswiler R; Küng M; Marti HP
J Am Soc Nephrol; 1998 Mar; 9(3):397-407. PubMed ID: 9513901
[TBL] [Abstract][Full Text] [Related]
14. Administration of SB203580, a p38 MAPK Inhibitor, Reduced the Expression of MMP9, and Relieved Neurologic Severity in the Experimental Autoimmune Neuritis (EAN) in Rats.
Sun Y; Chen H; Ma S; Liang L; Zheng Y; Guo X; Wang M; Wang W; Li G; Zhong D
Neurochem Res; 2015 Jul; 40(7):1410-20. PubMed ID: 25998885
[TBL] [Abstract][Full Text] [Related]
15. The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU).
Wallace GR; Whiston RA; Stanford MR; Wells GM; Gearing AJ; Clements JM
Clin Exp Immunol; 1999 Dec; 118(3):364-70. PubMed ID: 10594553
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration.
Demestre M; Wells GM; Miller KM; Smith KJ; Hughes RA; Gearing AJ; Gregson NA
Neuroscience; 2004; 124(4):767-79. PubMed ID: 15026117
[TBL] [Abstract][Full Text] [Related]
17. Anti-cytokine autoantibodies in experimental autoimmune neuritis in Lewis rats.
Zhu W; Mix E; Nennesmo I; Adem A; Zhu J
Exp Neurol; 2004 Dec; 190(2):486-94. PubMed ID: 15530887
[TBL] [Abstract][Full Text] [Related]
18. PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing T
Liu H; Wan C; Ding Y; Han R; He Y; Xiao J; Hao J
FASEB J; 2017 Apr; 31(4):1756-1766. PubMed ID: 28096232
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system.
Kurz M; Pischel H; Hartung HP; Kieseier BC
J Peripher Nerv Syst; 2005 Sep; 10(3):311-8. PubMed ID: 16221290
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1.
Archelos JJ; Mäurer M; Jung S; Miyasaka M; Tamatani T; Toyka KV; Hartung HP
Lab Invest; 1994 May; 70(5):667-75. PubMed ID: 8196363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
